Investigation of in vitro Efficacy of Miltefosine on Chronic Cutaneous Leishmaniasis
- 23 May 2022
- journal article
- research article
- Published by Galenos Yayinevi in Turkish Journal of Parasitology
- Vol. 46 (2) , 97-101
Abstract
Leishmaniasis is the second deadliest parasitic disease in the World Health Organisation's list of neglected diseases, following malaria. Cutaneous leishmaniasis (CL) is the most common form of the disease and it is one of the few communicable diseases with increasing incidence rates owing to factors like armed conflicts and climate change. CL can be divided into two major groups: Acute CL (ACL) and chronic CL (CCL). The aim of this study was to compare the in vitro efficacy of miltefosine and pentavalent antimony compounds in the CCL patient samples. Five isolates previously isolated from 5 CCL patients were included in this study. Genotyping is performed using internal transcribed spacer 1 (ITS 1) gene region real-time PCR. In vitro drug efficacy tests were applied to determine their activity against meglumine antimoniate (MA) and miltefosine. Serial dilutions (512, 256, 128, 64, 32, 16, 8 and 4 µg/mL) prepared from MA and miltefosine were prepared in 96-well flat-bottom cell culture plates and incubated at 24 °C for 48 hours. The efficacy of the drug on Leishmania spp. promastigotes after 24 and 48 hours was evaluated by hemocytometer slide and XTT cell viability test. All of the samples were genotyped as L. tropica. Evaluation of 24 and 48 hours showed, 128 µg/mL and 256 µg/mL and 32 µg/mL and 64 µg/mL concentrations of miltefosine and MA were enough to kill all the promastigotes respectively. The results of the hemocytometer slide and XTT were consistent. There are no studies investigating the in vitro efficacy of miltefosine with the CCL patient group. To overcome the treatment challenges experienced in this special patient group, more studies are needed. According to our results, it is concluded that miltefosine is efficient for the treatment of CCL and further clinical studies with miltefosine will reveal valuable data.Keywords
This publication has 21 references indexed in Scilit:
- A Real-Time ITS1-PCR Based Method in the Diagnosis and Species Identification of Leishmania Parasite from Human and Dog Clinical Samples in TurkeyPLOS Neglected Tropical Diseases, 2013
- Cutaneous Leishmaniasis in TurkeyTurkish Journal of Parasitology, 2012
- Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with MiltefosinePLOS Neglected Tropical Diseases, 2011
- Chronic cutaneous leishmaniasis, a great mimicker with various clinical presentations: 12 years experience from AleppoJournal of the European Academy of Dermatology and Venereology, 2011
- Miltefosine to treat cutaneous leishmaniasis caused byLeishmania tropicaPathogens and Global Health, 2009
- Drug Resistance in LeishmaniasisClinical Microbiology Reviews, 2006
- Oral Miltefosine for Leishmaniasis in Immunocompromised Patients: Compassionate Use in 39 Patients with HIV InfectionClinical Infectious Diseases, 2004
- Miltefosine for New World Cutaneous LeishmaniasisClinical Infectious Diseases, 2004
- Hydrosoluble formazan XTT: its application to natural products drug discovery for LeishmaniaJournal of Microbiological Methods, 2003
- Activities of Hexadecylphosphocholine (Miltefosine), AmBisome, and Sodium Stibogluconate (Pentostam) against Leishmania donovani in Immunodeficient scid MiceAntimicrobial Agents and Chemotherapy, 2001